Teva and Sanofi Accelerate Anti-TL1A Phase 2b Program for Inflammatory Bowel Disease
07/25/24, 5:36 AM
Location
tel avivMoney
$500 million
Industry
pharmaceutical
biotechnology
health care
manufacturing
Type
partnership
Teva and Sanofi have announced an accelerated timeline for the anti-TL1A program, including the completion of patient enrollment in the RELIEVE UCCD Phase 2b trial and the update to the timing for topline and detailed results. They are collaborating to co-develop and co-commercialize duvakitug for moderate-to-severe UC and CD patients.
Company Info
Location
tel aviv, tel aviv district, israel
Additional Info
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative medicines research and operations supporting our growing portfolio of innovative medicines and biopharmaceutical products.